A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations.

@article{Yoshioka2009API,
  title={A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations.},
  author={Hiroshige Yoshioka and Hideyuki Hayashi and Katsuyuki Kiura and Nagio Takigawa and Katsuyuki Hotta and Shingo Harita and Haruhito Kamei and Akihiro Bessho and Masahiro Tabata and Mitsune Tanimoto},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={8067}
}
8067 Background: Efficacy of gefitinib therapy strongly depends on the presence of active EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and only 1.1% in active mutant-positive (EGFRmt+) and -negative (EGFRmt-) tumors, respectively [Mok T, ESMO2008]. Recently, the survival advantage of erlotinib, another TKI, is observed… CONTINUE READING